Previous 10 | Next 10 |
RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophrenia GRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical development COMP360: Recently announced acceleration o...
Psychedelics are poised to revolutionize the psychiatric industry over the next couple of decades. In the midst of a global mental health crisis that has affected more than a billion people around the world, researchers have been working to develop psychedelic-assisted therapies to treat a my...
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. De...
Summary There have been some exciting developments in the research around the medicinal potential of psychedelic compounds. Despite a potential opportunity for disruption, investors should keenly understand the unique risks to biotechnology plays before investing in the space. Given...
In just a few short years, psychedelics have presented themselves as a potential alternative to pharmaceutical mental health therapies. Research into hallucinogenic drugs has revealed that they are capable of alleviating the symptoms of mental disorders, such as treatment-resistant depression...
After decades of prohibition by most territories, psychedelics are finally seeing a surge in interest among the scientific and mainstream communities. Initial research into the potential risks and benefits of psychedelic drugs has revealed that they may be able to alleviate the symptoms of a ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value. They’re also followi...
Drug reform supporters in Virginia recently secured a major win after Virginia senators voted in favor of a psilocybin-rescheduling bill. The initiative, introduced by Senator Ghazala Hashmi, would reschedule psilocybin to a lower schedule and establish a psilocybin advisory board to oversee th...
Psychedelics researchers keep coming up with news ways to help human health and wellness. And it’s not just mental health issues, such as PTSD and depression. Now chronic pain , stroke , and migraines are on the list as well. All the new development raises a question: Is th...
Lawmakers in three separate states have introduced legislation to legalize psychedelics in 2023, increasing the number of states in the Unite States that are considering psychedelic reform this session to more than a dozen. Recent research has revealed that psychedelic drugs such as psilocybi...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...